{"news_desk": "Business", "print_page": "3", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Patient activist groups in Argentina, Brazil, China, Russia and Ukraine will file challenges seeking to void patents for Gilead Sciences blockbuster hepatitis C drug Sovaldi; argue that $84,000 price tag for course of treatment is prohibitive; actions are sign that controversy surrounding the drug in United States has spread abroad.", "type_of_material": "News", "word_count": "905", "lead_paragraph": "A New York group is expected to announce Wednesday that it has filed challenges to patents on Sovaldi in Argentina, Brazil, China, Russia and Ukraine.", "pub_date": "2015-05-20T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "High Cost of Sovaldi Hepatitis C Drug Prompts a Call to Void Its Patents", "print_headline": "High Cost of Hepatitis C Drug Prompts a Call to Void Its Patents"}, "snippet": "A New York group is expected to announce Wednesday that it has filed challenges to patents on Sovaldi in Argentina, Brazil, China, Russia and Ukraine.", "multimedia": [{"height": 126, "url": "images/2015/05/20/business/20GILEAD/20GILEAD-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/05/20/business/20GILEAD/20GILEAD-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 480, "url": "images/2015/05/20/business/20GILEAD/20GILEAD-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "480", "xlarge": "images/2015/05/20/business/20GILEAD/20GILEAD-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/05/20/business/20GILEAD/20GILEAD-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/05/20/business/20GILEAD/20GILEAD-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Hepatitis", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Gilead Sciences Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Sovaldi (Drug)", "name": "subject"}, {"rank": "4", "is_major": "Y", "value": "Inventions and Patents", "name": "subject"}, {"rank": "5", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Argentina", "name": "glocations"}, {"rank": "7", "is_major": "N", "value": "Brazil", "name": "glocations"}, {"rank": "8", "is_major": "N", "value": "China", "name": "glocations"}, {"rank": "9", "is_major": "N", "value": "Russia", "name": "glocations"}, {"rank": "10", "is_major": "N", "value": "Ukraine", "name": "glocations"}], "blog": [], "_id": "555bdca338f0d82290bae66c", "source": "The New York Times"}